| COCP | combined oral contraceptive pill |
|---|---|
| COGTT | cortisone oral glucose tolerance test |
| COS | cheiro-oral syndrome; chief of staff; Clinical Orthopaedic Society; clinically observed seizures |
| IAOM | International Association of Oral Myology |
| KB | human oral epidermoid carcinoma cells; Kashin-Bek [disease]; ketone body; kilobyte; Kleihauer-Betke ... |
| contraceptives, oral, sequential | Drugs administered orally and sequentially for contraceptive purposes. (12 Dec 1998) |
|---|---|
| contraceptives, oral, synthetic | Oral contraceptives which owe their effectiveness to synthetic preparations. (12 Dec 1998) |
| poliovirus vaccine, oral | A live vaccine containing attenuated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used for routine immunization of children against polio. This vaccine induces long-lasting intestinal and humoral immunity. Killed vaccine induces only humoral immunity. Oral poliovirus vaccine should not be administered to immunocompromised individuals or their household contacts. (12 Dec 1998) |
| heterotrophic oral gastrointestinal cyst | A cyst of the oral cavity lined by gastric or intestinal mucosa from misplaced embryonic rests. (05 Mar 2000) |
| Simplified Oral Hygiene Index | An index that measures the current oral hygiene status based upon the amount of debris and calculus occurring on six representative tooth surfaces in the mouth; often used in field surveys of periodontal disease. (05 Mar 2000) |
| naso-oral | Relating to the nose and mouth. (05 Mar 2000) |
| surgery, oral | A dental specialty concerned with the diagnosis and surgical treatment of disease, injuries, and defects of the human oral and maxillofacial region. (12 Dec 1998) |
| diagnosis, oral | Examination of the mouth and teeth toward the identification and diagnosis of intraoral disease or manifestation of non-oral conditions. (12 Dec 1998) |
| oral | <anatomy> Pertaining to the mouth, taken through or applied in the mouth, as an oral medication or an oral thermometer. (18 Nov 1997) |
| oral biology | That aspect of biology devoted to the study of biological phenomena associated with the oral cavity in health and disease (e.g., dental caries, mastication, periodontal disease). (05 Mar 2000) |
| oral cancer | Cancer within the mouth. Please see MedicineNet site on ral cancer for more information. (12 Dec 1998) |
| oral candidiasis | <gastroenterology, microbiology, oncology> Infection with a fungus of the genus Candida. It is usually a superficial infection of the moist cutaneous areas of the body and is generally caused by Candida albicans, it most commonly involves the skin (dermatocandidiasis), oral mucous membranes (oral candidiasis), respiratory tract (bronchocandidiasis) and vagina (vaginal candidiasis or thrush). Rarely there is a systemic infection or endocarditis. Oral candidiasis: describes a fungal (yeast) infection of the oral cavity due to Candida. It is common in infants, diabetics or those on chemotherapy and is well recognised in patients with HIV infection and AIDS. Oesophageal candidiasis: Infection of the oesophagus by the yeast-like fungus Candidal albicans. Usually occurs in the immunocompromised individual (AIDS or following chemotherapy). Oral candidiasis is a predisposing factor but oesophageal involvement can occur without evidence of infection in the oral cavity. Symptoms include difficulty swallowing, pain on swallowing and oral lesions. Diagnosis is made using endoscopy. Treatment is with antifungal agents such as ketoconazole or fluconazole. Synonym: moniliasis, candidosis, oidiomycosis, blastodendriosis. (16 Dec 1997) |
| oral cavity | The region consisting of the vestibulum oris, the narrow cleft between the lips and cheeks, and the teeth and gums, and the cavitas oris propria. Synonym: cavitas oris, cavum oris, mouth. (05 Mar 2000) |
| oral cavity proper | The space between the dental arches, limited posteriorly by the isthmus of the fauces (palatoglossal arch). Synonym: cavitas oris propria. (05 Mar 2000) |
| oral cholecystogram | <radiology> Dose: 6 x 0.5 gram tablets after evening meal, peak opacification in 14-19 hrs. (13-35% excreted in urine) patient selection: bilirubin less than 5mg% (unless secondary to haemolysis), contraindicated in serious liver disease, relative contraindications in peritonitis, postoperative ileus, acute pancreatitis nonvisualization of gallbladder, cholecytectomy, obstruction of cystic duct, chronic cholecystitis, anomolous position of gall bladder, extrabiliary causes, fasting state, failure to reach absorptive surface of bowel (e.g. Malabsorption), deficiency of bile salts (Crohn disease, surgical resection of TI, liver disease, cholestyramine therapy, abnormal communication between biliary and GI tract) (12 Dec 1998) |